BiOMViS

Executive Summary

BiOMViS Srl is a privately held Italian biotechnology company leveraging a proprietary Outer Membrane Vesicle (OMV) platform derived from genetically engineered, non-pathogenic E. coli strains. Founded in 2018 and headquartered in Milan with operations in Siena, the company focuses on developing prophylactic vaccines and immunotherapies for infectious diseases and cancer. Its core technology aims to produce safe, highly immunogenic OMVs that can be tailored to display antigens from multiple pathogens or tumor-associated targets, potentially enabling rapid, cost-effective vaccine development. Despite limited public disclosures on specific pipeline candidates or funding, the platform's versatility positions BiOMViS as an early-stage player in the competitive OMV vaccine space. The company's progress is likely at the preclinical stage, with no disclosed clinical trials or partnerships to date. The OMV platform has precedent in approved vaccines (e.g., Bexsero for meningitis B), suggesting translational potential, but BiOMViS faces significant hurdles including manufacturing scale-up, regulatory validation, and differentiation from established OMV players. Given the early stage and lack of tangible milestones, near-term valuation remains speculative. However, success in generating proof-of-concept data could attract partnerships or funding to advance its pipeline toward clinical development.

Upcoming Catalysts (preview)

• Q3 2026Publication of preclinical proof-of-concept data in a peer-reviewed journal70% success
• Q4 2026Announcement of a lead candidate entering first-in-human clinical trial30% success
• Q2 2027Strategic partnership or licensing deal with a larger vaccine developer25% success